Add to ORKG7th International Eurasian Hematology Congress -- OCT 13-16, 2016 -- Istanbul, TURKEYWOS: 00039118060008
PurposeThe safety and efficacy of ibrutinib, a once-daily Bruton's tyrosine kinase (BTK) inhibitor, ...
Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive d...
Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive d...
8th International Eurasian Hematology Oncology Congress (EHOC) -- OCT 18-21, 2017 -- Istanbul, TURKE...
61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) -- DEC 07-10, 2019 --...
Contains fulltext : 201051.pdf (publisher's version ) (Closed access
Purpose of the study. To obtain experience with ibrutinib in patients with chronic lymphocytic leuke...
Ibrutinib, a Brutons tyrosine kinase inhibitor is approved for relapsed/refractory and del(17p)/TP53...
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic...
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated w...
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED W...
Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current...
The multicenter observational BiRD study investigated the real-world effectiveness and safety of ibr...
Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refra...
A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of...
PurposeThe safety and efficacy of ibrutinib, a once-daily Bruton's tyrosine kinase (BTK) inhibitor, ...
Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive d...
Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive d...
8th International Eurasian Hematology Oncology Congress (EHOC) -- OCT 18-21, 2017 -- Istanbul, TURKE...
61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) -- DEC 07-10, 2019 --...
Contains fulltext : 201051.pdf (publisher's version ) (Closed access
Purpose of the study. To obtain experience with ibrutinib in patients with chronic lymphocytic leuke...
Ibrutinib, a Brutons tyrosine kinase inhibitor is approved for relapsed/refractory and del(17p)/TP53...
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic...
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated w...
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED W...
Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current...
The multicenter observational BiRD study investigated the real-world effectiveness and safety of ibr...
Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refra...
A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of...
PurposeThe safety and efficacy of ibrutinib, a once-daily Bruton's tyrosine kinase (BTK) inhibitor, ...
Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive d...
Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive d...